Screening breast cancer patients for Norwegian ATM mutations.
483 Norwegian breast cancer patients were screened for six different ataxia telangiectasia mutated (ATM) mutations previously found to account for 83% of the disease alleles in Norwegian ataxia telangiectasia (AT) patients. Only one carrier was found. These results provide no evidence in favour of an excess risk of breast cancer associated with heterozygosity for classical AT mutations, but remain consistent with a maximum 2.4-fold increased risk.
Laake
K
K
Department of Genetics, The Norwegian Radium Hospital, Montebello, Oslo, 0310.
Vu
P
P
Andersen
T I
TI
Erikstein
B
B
Kåresen
R
R
Lonning
P E
PE
Skovlund
E
E
Børresen-Dale
A L
AL
D000483:Alleles; D064007:Ataxia Telangiectasia Mutated Proteins; D001943:Breast Neoplasms / Q000453:epidemiology / Q000235:genetics*; D018797:Cell Cycle Proteins; D004252:DNA Mutational Analysis; D004273:DNA, Neoplasm / Q000737:chemistry / Q000235:genetics; D004268:DNA-Binding Proteins; D005260:Female; D005787:Gene Frequency; D005838:Genotype; D006801:Humans; D008403:Mass Screening; D009664:Norway / Q000453:epidemiology; D017346:Protein Serine-Threonine Kinases / Q000235:genetics*; D025521:Tumor Suppressor Proteins
D018797:Cell Cycle Proteins; D004273:DNA, Neoplasm; D004268:DNA-Binding Proteins; D025521:Tumor Suppressor Proteins; C576324:ATM protein, human; D064007:Ataxia Telangiectasia Mutated Proteins; D017346:Protein Serine-Threonine Kinases